Prescribing Notes
- Refer to NICE guidance on anticoagulation treatment for venous thromboembolism (NICE make recommendations on preferred anticoagulant choices; these vary depending on co-morbidities/ clinical features. Apixaban is recommended first line in patients with no relevant co-morbidities or significant clinical features.)
- Please note dosing schedule. A number of incidents have been reported where the initial twice daily dose for rivaroxaban was continued beyond the 21 days following discharge from hospital, presenting a significant risk to patients. This type of incident is also possible with apixaban. Refer to BNF.
Cautions
See here.